Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/21645515.2021.1940650 http://scihub22266oqcxt.onion/10.1080/21645515.2021.1940650 34191682!9116391!34191682     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Hum+Vaccin+Immunother 2022 ; 18 (2): 1940650 Nephropedia Template TP {{tp|p=34191682|t=2022. Inhaled antibodies: Quality and performance considerations |pdf=|usr=}}{{34191682}} gab.com Text Inhaled antibodies: Quality and performance considerations JO: Hum Vaccin Immunother http://www.kidney.de/pget.php?&tw=1&pmid=34191682 #FOAvip The use of antibodies in the treatment of lung diseases is of increasing interest especially as the search for COVID-19 therapies has unfolded. Historically, the use of antibody therapy was based on multiple targets including receptors involved in local hyper-reactivity in asthma, viruses and micro-organisms involved in a variety of pulmonary infectious disease. Generally, protein therapeutics pose challenges with respect to formulation and delivery to retain activity and assure therapy. The specificity of antibodies amplifies the need for attention to molecular integrity not only in formulation but also during aerosol delivery for pulmonary administration. Drug product development can be viewed from considerations of route of administration, dosage form, quality, and performance measures. Nebulizers and dry powder inhalers have been used to deliver protein therapeutics and each has its advantages that should be matched to the needs of the drug and the disease. This review offers insight into quality and performance barriers and the opportunities that arise from meeting them effectively. Twit Text FOAVip Inhaled antibodies: Quality and performance considerations ????Hum Vaccin Immunother http://www.kidney.de/pget.php?&tw=1&pmid=34191682 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34191682 #FOAvip English Wikipedia <ref>{{Cite pmid|34191682}}</ref> Inhaled antibodies: Quality and performance considerations #MMPMID34191682 Hickey AJ; Stewart IE Hum Vaccin Immunother 2022[Apr]; 18 (2): 1940650 PMID34191682show ga The use of antibodies in the treatment of lung diseases is of increasing interest especially as the search for COVID-19 therapies has unfolded. Historically, the use of antibody therapy was based on multiple targets including receptors involved in local hyper-reactivity in asthma, viruses and micro-organisms involved in a variety of pulmonary infectious disease. Generally, protein therapeutics pose challenges with respect to formulation and delivery to retain activity and assure therapy. The specificity of antibodies amplifies the need for attention to molecular integrity not only in formulation but also during aerosol delivery for pulmonary administration. Drug product development can be viewed from considerations of route of administration, dosage form, quality, and performance measures. Nebulizers and dry powder inhalers have been used to deliver protein therapeutics and each has its advantages that should be matched to the needs of the drug and the disease. This review offers insight into quality and performance barriers and the opportunities that arise from meeting them effectively. |*Asthma[MESH] |*COVID-19[MESH] |Administration, Inhalation[MESH] |Aerosols/therapeutic use[MESH] |Antibodies/therapeutic use[MESH] |Drug Delivery Systems/methods[MESH] |Dry Powder Inhalers[MESH]Inhaled antibodies: Quality and performance considerations (epmc).pdf DeepDyve Pubget Overpricing